Ruy Perez-Montfort

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7568789/publications.pdf

Version: 2024-02-01

79 papers

2,058 citations

28 h-index 276539 41 g-index

80 all docs 80 docs citations

80 times ranked

1637 citing authors

#	Article	IF	CITATIONS
1	Pyrazol(in)e derivatives of curcumin analogs as a new class of anti-Trypanosoma cruzi agents. Future Medicinal Chemistry, 2021, 13, 701-714.	1.1	5
2	Native aggregation is a common feature among triosephosphate isomerases of different species. Scientific Reports, 2020, 10, 1338.	1.6	8
3	Key within-membrane residues and precursor dosage impact the allotopic expression of yeast subunit II of cytochrome c oxidase. Molecular Biology of the Cell, 2019, 30, 2358-2366.	0.9	5
4	Medical and Veterinary Importance of the Moonlighting Functions of Triosephosphate Isomerase. Current Protein and Peptide Science, 2019, 20, 304-315.	0.7	16
5	Differential effects on enzyme stability and kinetic parameters of mutants related to human triosephosphate isomerase deficiency. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1401-1409.	1.1	11
6	Novel and Selective Rhipicephalus microplus Triosephosphate Isomerase Inhibitors with Acaricidal Activity. Veterinary Sciences, 2018, 5, 74.	0.6	13
7	A strategy based on thermal flexibility to design triosephosphate isomerase proteins with increased or decreased kinetic stability. Biochemical and Biophysical Research Communications, 2018, 503, 3017-3022.	1.0	3
8	Three unrelated and unexpected amino acids determine the susceptibility of the interface cysteine to a sulfhydryl reagent in the triosephosphate isomerases of two trypanosomes. PLoS ONE, 2018, 13, e0189525.	1.1	1
9	The importance of arginine codons AGA and AGG for the expression in E. coli of triosephosphate isomerase from seven different species. Biotechnology Reports (Amsterdam, Netherlands), 2017, 13, 42-48.	2.1	1
10	A guide to the effects of a large portion of the residues of triosephosphate isomerase on catalysis, stability, druggability, and human disease. Proteins: Structure, Function and Bioinformatics, 2017, 85, 1190-1211.	1.5	27
11	The effect of specific proline residues on the kinetic stability of the triosephosphate isomerases of two trypanosomes. Proteins: Structure, Function and Bioinformatics, 2017, 85, 571-579.	1.5	6
12	Interplay between Protein Thermal Flexibility and Kinetic Stability. Structure, 2017, 25, 167-179.	1.6	29
13	Multi-Anti-Parasitic Activity of Arylidene Ketones and Thiazolidene Hydrazines against Trypanosoma cruzi and Leishmania spp Molecules, 2017, 22, 709.	1.7	25
14	Potent and Selective Inhibitors of <i>Trypanosoma cruzi</i> Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity. ChemMedChem, 2016, 11, 1328-1338.	1.6	38
15	Early expression of the receptor for advanced glycation end products in a toxic model produced by 6-hydroxydopamine in the rat striatum. Chemico-Biological Interactions, 2016, 249, 10-18.	1.7	8
16	First Record ofBartonella vinsoniiin the Sucking LouseHoplopleura hirsutaCollected from Hispid Cotton Rats,Sigmodon hispidus, in Mexico. Southwestern Entomologist, 2016, 41, 1031-1036.	0.1	3
17	Identification of the critical residues responsible for differential reactivation of the triosephosphate isomerases of two trypanosomes. Open Biology, 2016, 6, 160161.	1.5	6
18	3-H-[1,2]Dithiole as a New Anti-Trypanosoma cruzi Chemotype: Biological and Mechanism of Action Studies. Molecules, 2015, 20, 14595-14610.	1.7	11

#	Article	IF	CITATIONS
19	Development of bis-thiazoles as inhibitors of triosephosphate isomerase from Trypanosoma cruzi. Identification of new non-mutagenic agents that are active inÂvivo. European Journal of Medicinal Chemistry, 2015, 100, 246-256.	2.6	37
20	Modeling the Interaction between Quinolinate and the Receptor for Advanced Glycation End Products (RAGE): Relevance for Early Neuropathological Processes. PLoS ONE, 2015, 10, e0120221.	1.1	17
21	New chemotypes as <i>Trypanosoma cruzi</i> triosephosphate isomerase inhibitors: a deeper insight into the mechanism of inhibition. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 198-204.	2.5	19
22	Different contribution of conserved amino acids to the global properties of triosephosphate isomerases. Proteins: Structure, Function and Bioinformatics, 2014, 82, 323-335.	1.5	15
23	1,2,4-thiadiazol-5(4 <i>H</i>)-ones: a new class of selective inhibitors of <i>Trypanosoma cruzi</i> triosephosphate isomerase. Study of the mechanism of inhibition. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 981-989.	2.5	13
24	A Ribosomal Misincorporation of Lys for Arg in Human Triosephosphate Isomerase Expressed in Escherichia coli Gives Rise to Two Protein Populations. PLoS ONE, 2011, 6, e21035.	1.1	15
25	Structural and biochemical characterization of a recombinant triosephosphate isomerase from Rhipicephalus (Boophilus) microplus. Insect Biochemistry and Molecular Biology, 2011, 41, 400-409.	1.2	18
26	Identification of Amino Acids that Account for Long-Range Interactions in Two Triosephosphate Isomerases from Pathogenic Trypanosomes. PLoS ONE, 2011, 6, e18791.	1.1	15
27	Thermodynamic and Kinetic Destabilization of Triosephosphate Isomerase Resulting from the Mutation of Conserved and Non-conserved Cysteines. Protein and Peptide Letters, 2011, 18, 1290-1298.	0.4	4
28	Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. European Journal of Medicinal Chemistry, 2010, 45, 5767-5772.	2.6	47
29	PCR for identification of species causing American cutaneous leishmaniasis. Parasitology Research, 2009, 104, 691-699.	0.6	23
30	A monoclonal antibody that inhibits Trypanosoma cruzi growth in vitro and its reaction with intracellular triosephosphate isomerase. Parasitology Research, 2008, 102, 635-643.	0.6	19
31	Expression, purification and preliminary X-ray diffraction studies of the transcriptional factor PyrR fromBacillus halodurans. Acta Crystallographica Section F: Structural Biology Communications, 2008, 64, 692-696.	0.7	O
32	The conserved salt bridge linking two Câ \in terminal \hat{l}^2/\hat{l} ± units in homodimeric triosephosphate isomerase determines the folding rate of the monomer. Proteins: Structure, Function and Bioinformatics, 2008, 72, 972-979.	1.5	8
33	Key Residues of Loop 3 in the Interaction with the Interface Residue at Position 14 in Triosephosphate Isomerase from <i>Trypanosoma brucei</i> Isomerase from <i>Trypanosoma brucei</i>	1.2	12
34	Structural Basis of Human Triosephosphate Isomerase Deficiency. Journal of Biological Chemistry, 2008, 283, 23254-23263.	1.6	68
35	Perturbation of the Dimer Interface of Triosephosphate Isomerase and its Effect on Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2007, 1, e1.	1.3	44
36	Crosstalk between the subunits of the homodimeric enzyme triosephosphate isomerase. Proteins: Structure, Function and Bioinformatics, 2007, 67, 75-83.	1.5	8

#	Article	IF	CITATIONS
37	The Stability and Formation of Native Proteins from Unfolded Monomers Is Increased through Interactions with Unrelated Proteins. PLoS ONE, 2007, 2, e497.	1.1	10
38	Structural Differences in Triosephosphate Isomerase from Different Species and Discovery of a Multitrypanosomatid Inhibitor. Biochemistry, 2006, 45, 2556-2560.	1.2	58
39	Loosely packed papain prosegment displays inhibitory activity. Archives of Biochemistry and Biophysics, 2006, 446, 151-160.	1.4	13
40	Immunosuppressive activity of proteases in cervical carcinoma. Gynecologic Oncology, 2005, 98, 111-117.	0.6	13
41	Pyruvate Kinase Revisited. Journal of Biological Chemistry, 2005, 280, 37924-37929.	1.6	52
42	Kinetic Mechanism and Metabolic Role of Pyruvate Phosphate Dikinase from Entamoeba histolytica. Journal of Biological Chemistry, 2004, 279, 54124-54130.	1.6	24
43	An unusual triosephosphate isomerase from the early divergent eukaryote Giardia lamblia. Proteins: Structure, Function and Bioinformatics, 2004, 55, 824-834.	1.5	23
44	Conserved Cysteine 126 in Triosephosphate Isomerase Is Required Not for Enzymatic Activity but for Proper Folding and Stabilityâ€. Biochemistry, 2004, 43, 3255-3263.	1.2	61
45	Inactivation of Triosephosphate Isomerase from Trypanosoma cruzi by an Agent that Perturbs its Dimer Interface. Journal of Molecular Biology, 2004, 341, 1355-1365.	2.0	65
46	Control of the Reactivation Kinetics of Homodimeric Triosephosphate Isomerase from Unfolded Monomersâ€. Biochemistry, 2003, 42, 3311-3318.	1.2	47
47	Unfolding of Triosephosphate Isomerase from Trypanosoma brucei: Identification of Intermediates and Insight into the Denaturation Pathway Using Tryptophan Mutants. Archives of Biochemistry and Biophysics, 2002, 399, 117-129.	1.4	41
48	Highly specific inactivation of triosephosphate isomerase from Trypanosoma cruzi. Biochemical and Biophysical Research Communications, 2002, 295, 958-963.	1.0	62
49	Catalysis and Stability of Triosephosphate Isomerase from Trypanosoma brucei with Different Residues at Position 14 of the Dimer Interface. Characterization of a Catalytically Competent Monomeric Enzyme. Biochemistry, 2002, 41, 4230-4238.	1.2	25
50	Polymorphism analysis of the internal transcribed spacer and small subunit of ribosomal RNA genes of Leishmania mexicana. Parasitology Research, 2002, 88, 918-925.	0.6	46
51	Susceptibility to proteolysis of triosephosphate isomerase from two pathogenic parasites: Characterization of an enzyme with an intact and a nicked monomer. Proteins: Structure, Function and Bioinformatics, 2002, 48, 580-590.	1.5	27
52	The Interfaces of Oligomeric Proteins as Targets for Drug Design against Enzymes from Parasites. Current Topics in Medicinal Chemistry, 2002, 2, 457-470.	1.0	16
53	Factors That Control the Reactivity of the Interface Cysteine of Triosephosphate Isomerase from Trypanosoma brucei and Trypanosoma cruzi. Biochemistry, 2001, 40, 3134-3140.	1.2	27
54	Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Tropical Medicine and International Health, 1999, 4, 801-811.	1.0	40

#	Article	IF	CITATIONS
55	The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitology Research, 1999, 85, 165-170.	0.6	28
56	Derivatization of the Interface Cysteine of Triosephosphate Isomerase fromTrypanosoma bruceiandTrypanosoma cruzias Probe of the Interrelationship between the Catalytic Sites and the Dimer Interfaceâ€. Biochemistry, 1999, 38, 4114-4120.	1.2	36
57	Expression and characterization of recombinant pyruvate phosphate dikinase from Entamoeba histolytica. BBA - Proteins and Proteomics, 1998, 1382, 47-54.	2.1	37
58	Sulfhydryl reagent susceptibility in proteins with high sequence similarity. Triosephosphate isomerase from Trypanosoma brucei, Trypanosoma cruzi and Leishmania mexicana. FEBS Journal, 1998, 253, 684-691.	0.2	47
59	Differences in the intersubunit contacts in triosephosphate isomerase from two closely related pathogenic trypanosomes. Journal of Molecular Biology, 1998, 283, 193-203.	2.0	68
60	Reactivation of triosephosphate isomerase from three trypanosomatids and human: effect of Suramin. Biochemical Journal, 1998, 332, 91-96.	1.7	11
61	A Mechanism of Acquired Resistance to Complement-Mediated Lysis by Entamoeba histolytica. Journal of Parasitology, 1997, 83, 234.	0.3	11
62	Purification of Alcohol Dehydrogenase fromEntamoeba histolyticaandSaccharomyces cerevisiaeUsing Zinc-Affinity Chromatography. Protein Expression and Purification, 1997, 10, 340-344.	0.6	7
63	Cloning, Expression, Purification and Characterization Of Triosephosphate Isomerase from Trypanosoma Cruzi. FEBS Journal, 1997, 244, 700-705.	0.2	48
64	Insular Cortex Lesions Impair the Acquisition of Conditioned Immunosuppression. Brain, Behavior, and Immunity, 1996, 10, 103-114.	2.0	38
65	Species-Specific Inhibition of Homologous Enzymes by Modification of Nonconserved Amino Acids Residues. The cysteine residues of triosephosphate isomerase. FEBS Journal, 1996, 241, 114-120.	0.2	33
66	Using evolutionary changes to achieve species-specific inhibition of enzyme action $\hat{a} \in "$ studies with triosephosphate isomerase. Chemistry and Biology, 1995, 2, 847-855.	6.2	66
67	Cloning and sequence determination of the gene coding for the pyruvate phosphate dikinase of Entamoeba histolytica. Gene, 1994, 142, 249-251.	1.0	14
68	Pathogenesis of Acute Experimental Amebic Liver Abscess in Hamsters. Journal of Parasitology, 1991, 77, 982.	0.3	18
69	Causes of the decrease in fluorescence due to proteolysis of \hat{l}_{\pm} -casein. BBA - Proteins and Proteomics, 1990, 1041, 146-152.	2.1	7
70	Proteinases of Entamoeba histolytica associated with different subcellular fractions. Molecular and Biochemical Parasitology, 1989, 32, 133-143.	0.5	21
71	Measurement of casein digestion by a fluorometric method. Analytical Biochemistry, 1989, 176, 239-243.	1.1	12
72	Entamoeba histolytica: Role of amebic proteinases and polymorphonuclear leukocytes in acute experimental amebiasis in the rat. Experimental Parasitology, 1988, 67, 268-280.	0.5	23

#	Article	IF	CITATION
73	Vasoactive Intestinal Peptide. A Possible REM Sleep Factor. Annals of the New York Academy of Sciences, 1988, 527, 627-630.	1.8	8
74	Catalytic classes of proteinases of Entamoeba histolytica. Molecular and Biochemical Parasitology, 1987, 26, 87-97.	0.5	45
75	Noncovalently and covalently bound lipid on the receptor for immunoglobulin E. Biochemistry, 1985, 24, 7342-7348.	1.2	40
76	Analysis of the structure and function of the receptor for immunoglobulin E. Molecular Immunology, 1984, 21, 1167-1173.	1.0	31
77	A previously unrecognized subunit of the receptor for immunoglobulin. Biochemistry, 1983, 22, 5722-5728.	1.2	83
78	Covalent crosslinking of subunits of the receptor for immunoglobulin E induced by immunoprecipitation. Biochemistry, 1983, 22, 5729-5732.	1.2	16
79	Proteolysis of soluble Ige-receptor complexes: Localization of sites on IgE which interact with the Fc receptor. Molecular Immunology, 1982, 19, 1113-1125.	1.0	62